The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
A batch of new medicines will join the NHI price list on August 12, including Chugai Pharmaceutical’s Evrysdi (risdiplam), which marks the first oral treatment for spinal muscular atrophy (SMA), as well as Gilead Sciences’ COVID-19 drug Veklury (remdesivir). The…
To read the full story
Related Article
- Meiji Pharma Rolls Out ATLL Drug Hiyasta in Japan
October 21, 2021
- Veklury’s Normal Distribution in Japan to Start from Oct. 18
September 29, 2021
- Heart Failure Med Verquvo Makes Japan Debut: Bayer
September 16, 2021
- Poxel/Sumitomo Dainippon to Launch Twymeeg on Sept. 16
September 13, 2021
- Alnylam’s 2nd siRNA Therapy Givlaari Hits Japan Market
August 31, 2021
- Otsuka Launches Migraine Drug Ajovy in Japan
August 31, 2021
- Sanwa Kagaku Rolls Out Upasita for Secondary Hyperparathyroidism
August 20, 2021
- 1st Drug for Short Bowel Syndrome Now Available in Japan: Takeda
August 19, 2021
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
- Evrysdi, Aimovig Now Available; Veklury’s Normal Distribution to Start around October
August 13, 2021
- Veklury Distribution via Govt Purchase to Continue for Now: MHLW
August 6, 2021
- Ofev Faces 10%-Plus Cut in Quarterly Price Review; Veklury Gets Listing but No Copay for Now
August 5, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
- Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
REGULATORY
- Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
- Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025
- Japan Drops Transitional Plan for PCV20 Routine Shot in Elderly
December 23, 2025
- Tecartus Now in Line for Orphan Status with Japan Panel Nod
December 23, 2025
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…